Finance

Lists
Why is LENZ down 4,62%?
Dive Deeper
LENZ:NASDAQ
Lenz Therapeutics Inc
3,62 $
-4,62%
(-0,17) 1D
7 հոկ, 09:59:16 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LENZ...
Open
3,72 $
High
3,72 $
Low
3,61 $
Mkt. cap
113,27 մլն
Avg. vol.
738,24 հզր
Volume
40,10 հզր
52-wk high
49,24 $
52-wk low
3,46 $
EPS
-4,08 $
Beta
0,65
Shares outstanding
31,42 մլն
No. of employees
152
Open
3,72 $
High
3,72 $
Low
3,61 $
Mkt. cap
113,27 մլն
Avg. vol.
738,24 հզր
Volume
40,10 հզր
52-wk high
49,24 $
52-wk low
3,46 $
EPS
-4,08 $
Beta
0,65
Shares outstanding
31,42 մլն
No. of employees
152
News stories
From web sources and news partners
About Lenz Therapeutics Inc
CEO-
Employees152
Founded2013
HeadquartersSolana Beach, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitelenz-tx.com
Analyst ratings
Based on 6 analysts giving stock ratings to LENZ in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for LENZ in the last 3 months.
Highest
Current 3,62 $
60,00 $ (+1 559,75%)
Average
24,40 $ (+574,97%)
Lowest
7,00 $ (+93,64%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Hold
Downgraded
7,00 $
+93,6%
08/12/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/12/2026
Biren Amin
Piper Sandler
Hold
Maintained
7,00 $
+93,6%
08/12/2026
Yigal Nochomovitz
Citi
Buy
Maintained
10,00 $
+176,6%
08/13/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
38,00 $
+951,2%
08/12/2026
Stacy Ku
TD Cowen
Buy
Reiterated
60,00 $
+1 559,8%
08/12/2026
Last report
11 օգս, 2026 թ.
Fiscal period
Q2 2026
-1,02 $ / -1,07 $
+5,10%beat
Revenue / Est. (USD)
5,49 մլն / 2,38 մլն
+130,76%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
12,50 մլն
1,59 մլն
1,90 մլն
5,49 մլն
Cost of goods sold
-
418,00 հզր
1,08 մլն
280,00 հզր
Cost of revenue
-
418,00 հզր
1,08 մլն
280,00 հզր
Research and development expenses
3,79 մլն
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,60 մլն
39,63 մլն
44,96 մլն
39,38 մլն
Operating expense
31,39 մլն
39,63 մլն
44,96 մլն
39,38 մլն
Total operating expenses
31,39 մլն
40,05 մլն
46,04 մլն
39,66 մլն
Operating income
-18,89 մլն
-38,46 մլն
-44,14 մլն
-34,17 մլն
Other non operating income
-14,00 հզր
-417,00 հզր
3,00 հզր
-13,00 հզր
EBT including unusual items
-16,70 մլն
-35,89 մլն
-41,49 մլն
-31,92 մլն
EBT excluding unusual items
-16,70 մլն
-35,89 մլն
-41,49 մլն
-31,92 մլն
Income tax expense
-
2,00 հզր
-
3,00 հզր
Effective tax rate
-
-0,01%
-
-0,01%
Other operating expenses
-
-
-
-
Net income
-16,70 մլն
-35,90 մլն
-41,49 մլն
-31,92 մլն
Net profit margin
-133,60%
-2 260,45%
-2 182,43%
-581,81%
Earnings per share
-0,59
-1,16
-1,32
-1,02
Interest and investment income
2,20 մլն
2,99 մլն
2,64 մլն
2,27 մլն
Interest expense
-
-
-
-
Net interest expenses
2,20 մլն
2,99 մլն
2,64 մլն
2,27 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-18,76 մլն
-38,36 մլն
-44,02 մլն
-34,06 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps